Onconetix focused on cultivating key partnerships, acquiring vital assets

Onconetix issued a shareholder letter from the Company’s CEO Dr. Neil Campbell, which read in part, “As 2023 draws to a close, I am eager to share with you the significant strides Onconetix has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategic shifts and notable achievements, all aimed at enhancing the value we bring to you as our shareholders. To reflect our recent achievements and renewed oncology focus, we have rebranded as Onconetix, Inc. This rebranding reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics, and services for the treatment of cancer. A key component of our focus is Entadfi, an FDA-approved, once-daily oral treatment for benign prostatic hyperplasia. Set for launch in 2024, Entadfi is poised to be an important product in our oncology therapeutics portfolio and has the potential to be a first-line treatment for BPH symptoms. However, our larger strategy and vision for our commercial portfolio is a dual therapeutic and diagnostic approach. With our recent acquisition of Proteomedix, a commercial stage European oncology diagnostics company headquartered in Zurich, Switzerland, we have achieved just that. Now our cornerstone products are Entadfi for the treatment of benign prostatic hyperplasia and Proclarix for prostate cancer diagnostics. In addition to significantly enhancing our emerging commercial portfolio, the acquisition of Proteomedix and its diagnostic platform marks a milestone in expanding our diagnostic capabilities worldwide. Proclarix is CE-certified and adhering to both European and American guidelines. Proclarix is already available in Europe and will be introduced in the U.S. through an exclusive partnership with a U.S. major laboratory corporation. Joining the senior management team of Onconetix will be Dr. Ralph Schiess, PhD, co-founder of Proteomedix, as Chief Science Officer, and Mr. Christian Bruhlmann, co-founder of Proteomedix, as Chief Strategy Officer and General Manager of Europe. Finally, in line with our commitment to oncology, we have transitioned away from our preclinical vaccine programs. These programs are now transitioning back to our vaccine partners, ensuring their continued progress by others while we direct our resources towards more targeted initiatives in oncology. As you can see, our strategy, bolstered by our latest acquisition, lays a solid foundation for Onconetix in the oncology sphere. We are focused on cultivating key partnerships, acquiring vital assets, and initiating our commercial revenue phase. Our goal is to build a company that is not only focused on growth for shareholders, but also on providing innovative solutions to clinicians, patients, and caregivers.”